

PUBBLICAZIONI SCIENTIFICHE

PUBBLICAZIONI SCIENTIFICHE SU RIVISTE INTERNAZIONALI SOTTOPOSTE A GIUDIZIO DI REVISIONE

1. Favalli C. Mastino A., Jezzi T., **Grelli S.**, Goldstein A.L. and Garaci E. Synergistic effect of thymosin α 1 and $\alpha\beta$ interferon on NK activity in tumor bearing mice. **Int. J. Immunopharmacol.** 11: 5: 443-450, 1989. **I.F. 2.066.**
2. Mastino A., Favalli C., Jezzi T., **Grelli S.**, Pica F., Garaci E. Modification in spleen lymphocyte subsets after cyclophosphamide and Di-M-PGE2 administration in mice. **J. Chemother.** 4: 454-456, 1989. **I.F. 0.922.**
3. Mastino A., Favalli C., Moras M.L., **Grelli S.**, Bonmassar E. Flow cytometric method for the evaluation of the biological activity of thymic hormones. **J. Chemother.** 4: 459-460, 1989. **I.F. 0.922.**
4. Pica F., Mastino A., **Grelli S.**, Jezzi T., Favalli C. Combined treatment with Thymosin alpha 1 and interferon enhances NK activity in immunosuppressed tumor bearing mice. **J. Chemother.** 4: 1167-1169, 1989. **I.F. 0.922.**
5. Mastino A., Favalli C., **Grelli S.**, Innocenti F., and Garaci E. Thymosin α 1 potentiates interleukin 2-induced cytotoxic activity in mice. **Cell. Immunol.** 133: 196-205, 1991. **I.F. 1.808.**
6. Mastino A., **Grelli S.**, Premrov M.G., Favalli C. Susceptibility to Influenza A virus infection in mice immunosuppressed with cyclophosphamide. **J. Chemother.** 3: 156-161, 1991. **I.F. 0.922.**
7. Mastino A., Favalli C., **Grelli S.**, Rasi G., Pica F., Goldstein A.L. and Garaci E. Combination Therapy with thymosin α 1 potentiates the anti-tumor activity of interleukin 2 with cyclophosphamide in treatment of Lewis lung carcinoma in mice. **Int. J. Cancer.** 50: 493-499, 1992. **I.F. 4.555.**
8. Mastino A., Piacentini M., **Grelli S.**, Favalli C., Autori F., Tentori L., Oliviero S. and Garaci E. Induction of apoptosis in thymocytes by prostaglandin E2 in vivo. **Dev. Immunol.** 2: 263-271, 1992.
9. Mastino A., Favalli C., **Grelli S.** and Garaci E. Thymic hormones and cytokines. **Int. J. Immunophatol. Pharmac.** 5: 2: 77-82, 1992. **I.F. 4.665.**
10. Mastino A., **Grelli S.**, Piacentini M., Oliviero S., Favalli C., Perno C.F., Garaci E. Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV. **Cell.Immunol.** 152: 120-130, 1993. **I.F. 1.802.**

11. Garaci E., Rocchi G., Perroni L., D'Agostini C., Soscia F., **Grelli S.**, Mastino A., Favalli C. Combination treatment with zidovudine, thymosin α 1 and interferon- α in HIV infection. **Int. J.Clin. Lab. Res.** 24: 23-28,1994.
12. Venditti A., Scimò M.T., Del Poeta G., Buccisano F., Stasi R., Mastino A., **Grelli S.**, Favalli C., Garaci E. and Papa G. Recombinant interferon α 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study. **Leuk. Lymphoma** 16: 335-342, 1995.
13. Macchi B., Faraoni I., Zhang J., **Grelli S.**, Favalli C., Mastino A., Bonmassar E. 3'-Azido-3'-deoxythymidine (AZT) inhibits the transmission of human T-cell leukemia/lymphoma virus type 1(HTLV-1) to adult peripheral blood mononuclear cells in vitro. **J. Gen. Virol.** 78: 1007-1016, 1997. **I.F. 3.120**
14. Mastino A., **Grelli S.**, Favalli C., Matteucci C., De Carli M., Garaci E. and Macchi B. Interleukin 4 stimulates infection and temporary growth of human neonatal lymphocytes exposed *in vitro* to human HTLV-1, but fails to substitute for interleukin 2 in the immortalization of infected cultures. **J. Gen. Virol.** 78: 2565-2574, 1997. **I.F. 3.120**
15. Mastino A., Sciortino M.T., Medici M.A., Perri D., Amendolia M.G., **Grelli S.**, Amici C., Pernice A., Guglielmino S. Herpes simplex virus 2 causes apoptotic infection in monocytoic cells. **Cell Death Diff.** 4: 629-638, 1997. **I.F. 8.254.**
16. Macchi B., **Grelli S.**, Favalli C., De Carli M., Garaci E., Mastino A. Characterization of interleukin 2 and interleukin 4 dependent T cell lines infected with HTLV-1 in vitro. Macchi B., Grelli S., Favalli C., De Carli M. Garaci E., Mastino A. **Int. J Immunopathol and Pharmacol.** 10: 189-194, 1997. **I.F. 4.665.**
17. **Grelli S.**, Matteucci C., Cioli D., El-Sayed L.H., Adam N., Ghoneim H., De Smaele E., Favalli C., Garaci E. and Mastino A. Immunological events during the early phase of infection with *Schistosoma mansoni* in mice. **Int. J. Immunopathol Pharmacol.** 10: 205-211, 1997. **I.F. 4.665.**
18. Galante A., Pietroiusti A., Magrini A., Carta S., Franceschelli L., Piccolo P., Pistoiese G.R., Martelli E., Mastino A., Matteucci C., **Grelli S.**, Favalli C. Leucocyte rheological properties are altered in patients with diffuse atherosclerosis. **Thromb. Haemostasis** 77: 1073-1076, 1997. **I.F. 3.501.**
19. Formisano R., **Grelli S.**, Matteucci C., Santilli V., Vinicola V., Scivoletto G., Castellano V., D'Agostini C., Mastino A. and Favalli C. Immunological and endocrinological disturbances in patients after prolonged coma following head injury. **Eur. J. Neurol.** 5: 151-158, 1998. **I.F. 2.580.**

20. Macchi B., **Grelli S.**, Matteucci C., D'Elios M., De Carli M., Favalli C., Del Prete G. and Mastino A. Human Th1 and Th2 T-cell clones are equally susceptible to infection and immortalization by human T-lymphotropic virus type I (HTLV-1). **J. Gen. Virol.** 79: 2469-2474, 1998. **I.F. 3.120.**
21. Matteucci C., **Grelli S.**, De Smaele E., Fontana C. and Mastino A. Identification of nuclei from apoptotic, necrotic and viable lymphoid cells using multiparametric flow cytometry. **Cytometry** 35: 145-153, 1999. **I.F. 2.978.**
22. Giuliani C., Napolitano G., Mastino A., Di Vincenzo S., D'Agostini C., **Grelli S.**, Bucci I., Singer DS., Kohn Ld., Monaco F., Garaci E., Favalli C. Thymosin-alpha 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. **Eur. J. Immunol.** 30: 778-786, 2000. **I.F. 4.662.**
23. Galante A., Pietroiusti A., Carta S., Franceschelli L., Piccolo P., Mastino A., Fontana C, **Grelli S.**, Bergamaschi A., Magrini A., Favalli C. 2000. Infection with Helicobacter pylory and leukocyte responce in patients with myocardial infarction. **Eur. J. Clin. Microbiol. Infect. Dis.** 19: 298-300, 2000. **I.F. 2.309.**
24. **Grelli S.**, Campagna S., Lichtner M., Ricci G., Vella S., Vullo V., Montella F., Di Fabio S., Favalli C., Mastino A., Macchi B. Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy. **AIDS.** 14: 939-949, 2000. **I.F. 5.842.**
25. **Grelli S.**, Di Traglia L., Matteucci C., Lichtner M., Vullo V., Di Sora F., Lauria F., Montella F., Favalli C., Vella S., Macchi B., Mastino A. Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-RNA suppression. **AIDS.** 15: 1178-1181, 2001. **I.F. 5.842.**
26. Zhang J., Balestrieri E., **Grelli S.**, Mattucci C., Pagnini V., D'Agostini C., Mastino A., Macchi B. Efficacy of 3'-azido 3'-deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blod mononuclear cells. **Virus Res.** 78: 67-78, 2001. **I.F. 2.810.**
27. Mastino A., Favalli C., Camilli A.R., Malerba C., **Grelli S.**, Calugi A. Unbilical cord blood: the role of apoptosis in the control of CD34+ cell counts. **Placenta** 24: 113-115, 2003. **I.F. 3.238.**
28. **Grelli S.**, D'Ettore G., Lauria F., Montella F., Di Traglia L., D'Agostini C., Lichtner M., Vullo V., Favalli C., Vella S., Macchi B., Mastino A. CD4+ lymphocyte increseases in HIV patients during potent antiretroviral

therapy are dependent on inhibition of CD8+ cell apoptosis. **Ann N.Y. Acad. Sci.** 1010: 560-564, 2003. **I.F. 1.731.**

29. **Grelli S.**, D'Ettoire G., Lauria F., Montella F., Di Traglia L., Lichtner M., Vullo V., Favalli C., Vella S., Macchi B., Mastino A. Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. **J. Antimicrob. Chemother.** 53: 494-500, 2004. **I.F. 4.038.**
30. Tacconi S., Perri R., Balestrieri E., **Grelli S.**, Bernardini S., Annichiarico R., Mastino A., Caltagirone C., Macchi B. Increase caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. **Exp. Neurol.** 190: 254-262, 2004. **I.F. 3.982.**
31. D'Agostini C., Pica F., Febbraio G., **Grelli S.**, Chiavaroli C., Garaci E. Antitumor effect of OM-174 and cyclophosphamide on murine B-16 melanoma in different experimental conditions **Int. Immunopharmacol.** 5: 1205-1212, 2005. **I.F. 2.066.**
32. Mango R., Biocca S., del Vecchio F., Clementi F., Sangiuolo F., Amati F., Filareto A., **Grelli S.**, Spitalieri P., Filasi I., Favalli C., Lauro R., Mehta JL., Romeo F., Novelli G. In vivo and in vitro studies support the a new splicing isoform of ORL1 gene is protective against acute myocardial infarction. **Circ. Res.** 97: 152-158, 2005. **I.F. 9.251.**
33. Sciortino MT, Perri D, Medici MA, **Grelli S**, Serafino A, Borner C, Mastino A. Role of Bcl-2 expression for productive herpes simplex virus 2 replication. **Virology.** 356: 136-146, 2006. **I.F. 3.765.**
34. **Grelli S.**, Balestrieri E., Matteucci C., Minutolo A., d'Ettoire G., Lauria F., Montella F., Vullo V., Vella S., Favalli C., Mastino A., Macchi B. Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy. **Ann. N Y Acad. Sci.** 1090: 130-137, 2006. **I.F. 1.731.**
35. Balestrieri E., **Grelli S.**, Matteucci C., Minutolo A., d'Ettoire G., Di Sora F., Montella F., Vullo V., Vella S., Favalli C., Macchi B., Mastino A. Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. **J. Med.Virol.** 79: 111-117, 2007. **I.F. 2.831.**
36. Sciortino M.T., Medici MA, Marino-Merlo F, Zaccaria D, Giuffre M, Venuti A, **Grelli S**, Mastino A. Signaling pathway used by HSV-1 to induce NF-kappaB activation: possible role of herpes virus entry receptor A. **Ann N Y Acad Sci.** 1096: 89-96, 2007. **I.F. 1.731.**
37. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffrè-Cuculietto M, Venuti A, **Grelli S**, Mastino A. Involvement of HVEM receptor in

activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D. **Cell Microbiol.** 10: 2297-2311, 2008. **I.F. 5.725.**

38. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffrè-Cuculletto M, Venuti A, **Grelli S**, Bramanti P, Mastino A. Involvement of gD/HVEM interaction in NF-kB-dependent inhibition of apoptosis by HSV-1 gD. **Biochem Pharmacol.** 76: 1522-1532, 2008. **I.F. 4.254.**
39. Matteucci C, Minutolo A, Balestrieri E, Ascolani A, **Grelli S**, Macchi B, Mastino A. Effector caspase activation, in the absence of a conspicuous apoptosis induction, in mononuclear cells treated with azidothymidine. **Pharmacol Res.** 59: 125-33, 2009. **I.F. 3.929.**
40. Macchi B., Minutolo A., **Grelli S**, Cardona F., Corsero F., Mastino A., Brandi A The novel proapoptotic activity of non-natural enantiomer of Lentiginosine. **Glycobiology.** 20: 500-506. 2010. **I.F. 4.539.**
41. [Kalimutho M](#), [Minutolo A](#), [Grelli S](#), [Formosa A](#), [Sancesario G](#), [Valentini A](#), [Federici G](#), [Bernardini S](#). Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. **Cancer Chemother Pharmacol.** 2010 **I.F. 1.598**

CAPITOLI DI LIBRI, PUBBLICAZIONI SU RIVISTE NAZIONALI ED ATTI CONGRESSI

42. Favalli C., Mastino A., **Grelli S.**, Garaci E. Correlation between the effects of prostaglandins and interferon on B-16 melanoma growth and their modulation on natural killer activity. In **“Advances in Prostaglandin, Thromboxane, and Leukotriene Research”** Samuelsson B., Paoletti R. and Ramwell P.W. Eds. Vol. 17, p. 159-162. Raven Press. New York. 1987.
43. Mastino A., Pica F., Marini S., **Grelli S.**, Favalli C. Effetto di timosina alfa 1 ed IFN sull'attività NK in topi portatori di melanoma B-16. In **“Atti del XV Congresso Nazionale della Società Italiana di Chemioterapia”**. De Rosa F. Ed. p. 335-337. CIC Ed. Int. Roma. 1987.
44. Jezzi T., Mastino A., Pica F., Marini S., **Grelli S.**, Favalli C. Effetto delle PGE2 sul rilascio di IL 2 in animali normali e portatori di tumore. In **“Atti del XV Congresso Nazionale della Società Italiana di Chemioterapia”**. De Rosa F. Ed.p. 339-341. CIC Ed. Int. Roma. 1987.
45. Favalli C., Mastino A., Jezzi T., Pica F., **Grelli S.**, and Garaci E. Interaction between thymic hormones and other immunomodulating agents on the cell-mediated immune response. **Farmaci e Terapia**, 4, 6, 13, 1987.

46. Mastino A., Favalli C., **Grelli S.**, Pica F., and Garaci E. Effects of in vivo administration of Di-M-PGE2 on spleen and thymus subsets in mice. **Farmaci e Terapia**, 5, 5, 16, 1988.
47. Mastino A., Favalli C., **Grelli S.** and Garaci E. Flow cytometry analysis of spleen and thymus lymphoid cell subsets after cyclophosphamide administration in mice. **Farmaci e Terapia**, 5, 5, 59, 1988.
48. Mastino A., **Grelli S.**, Favalli C., Garaci E. Effect of Di-M-PGE2 on T cell differentiation. Flow cytometry study at thymus level. In **"Advances in Prostaglandins, Thromboxane and Leukotriene Research Series"** Samuelsson B., Paoletti R., Ramwell P.V. Eds. p. 851-854. Raven Press. New York.1990.
49. Mastino A., Favalli C., **Grelli S.** and Garaci E. Modulation of spleen and thymus lymphoid subsets by in vivo administration of Di-M-PGE2 in normal and tumor-bearing mice. In **"Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury"** Honn K.V., Marmett L.J., Nigam S., and Waldem T. Eds p. 259-263. Kluwer Academic Publishing. Boston.1991.
50. Favalli C., Mastino A., **Grelli S.**, Pica F., Rasi G., and Garaci E. Rationale for therapeutic approaches with thymic hormones interleukin 2 and interferon in combination with chemotherapy. In: **"New Frontiers in the Therapy of Malignancies: from Biological Approaches to Clinical Trials"** Mantovani G., Bonavida B., Del Giacco G.S., Granger G. A. and Kirkwood J.M. Eds. p. 47-56. Serono Symposia Review No. 25, 1991.
51. Mastino A., Favalli C., **Grelli S.**, Garaci E. Interaction between thymic hormones and other immunomodulatory agents. **Ann. Ist. Super. San.** 27, 1, 51-56, 1991.
52. Favalli C., Mastino A., **Grelli S.**, Rasi G., Garaci E. Effect of immunomodulatory agents in B-16 melanoma bearing mice. **Chronica Dermatologica.** 3, 460-461, 1992.
53. Favalli C., Mastino A., **Grelli S.**, Pica F., Rasi G., Garaci E. Rationale for therapeutic approaches with thymosin α 1, interleukin 2 and interferon in combination with chemotherapy. In **"Combination Therapy"** Goldstein A.L. and Garaci E. Eds. p. 275-281. Plenum Publishing Corporation. New York.1992.
54. Favalli C., Mastino A., Grelli S., Garaci E. Rationale for combination therapies with thymosyn α 1 and cytokines in infectious diseases. In **"Fifth International Symposium on Clinical and Environmental Microbiology"** Turano A. Ed. p. 22-28. Brixia Academic Press. Brescia. 1992.

55. Mastino A., **Grelli S.**, Staglianò M., Innocenti F., Favalli C. Analysis of lymphocyte subsets during B-16 melanoma tumor growth in mice. In: **"Clinical Chemistry and Enzimology Communication"**. Melino G, Knight A.R., Schwab M., Thiele J.C. Eds. Vol. 6, p. 99-104. Harwood Academy Publishers. 1993.
56. Garaci E., Rocchi G., Perroni L., D'Agostini C., Soscia F., Mastino A., **Grelli S.**, Perno C.F., Favalli C. Combined therapy with zidovudine thymosin α 1 and α interferon in the treatment of HIV-infected patients. In **"Combination Therapies 2"** Goldstein A.L: and Garaci E. Eds. p. 235-242. Plenum Publishing Corporation. New York. 1993.
57. Mastino A., Favalli C. Perroni L., D'Agostini C., Soscia F., Staglianò M., **Grelli S.**, Garaci E. Combination Therapies in Human Immunodeficiency Virus Infection. In **"Immunotherapy of infection"** Masihi K.N. Ed. p. 123-133. Marcel Dekker Inc., New York.1994.
58. Formisano R., **Grelli S.**, Mastino A., Santilli V., Di Diego G., Scivoletto G., Castellano V., Favalli C. Immunodeficiency and endocrinological disturbances in patient after prolonged coma of traumatic or hypoxic genesis: **Atti del 3° Convegno Nazionale del Gruppo di Studio Intersocietario di Riabilitazione Neurologica.** 71-73, 1994.
59. **Grelli S.**, Macchi B., Favalli C., Staglianò M., Matteucci C., Garaci E., and Mastino A. Studies on the induction of human lymphocyte apoptosis by prostaglandin E2. **Fundamental and Clinical Immunology**, Italian Federation of Immunological Societies Vol. 3, p. 86-87. Edi Ermes 1995.